Abstract : Adoptive transfer of T cells remains a promising approach in melanoma. Initial clinical trials performed with polyclonal tumor-infiltrating lymphocyte gave limited clinical results. Nonetheless, encouraging results have been reported in adjuvant setting (stage III melanoma), and when tumor-infiltrating lymphocytes were associated with lymphodepleting regimens. Specificity of adoptive cell therapy has been achieved with the infusion of antigen specific cytotoxic T-lymphocyte clones, associated with some clinical responses. Antigen specificity can also be obtained by the allogeneic transfer of high-avidity T-cell receptors into autologous T cells. We propose an alternative strategy based on the selection of antigen-specific T cells with magnetic beads coated with HLA-peptide multimers. Future improvements of adoptive melanoma immunotherapy may be achieved by its association with other therapeutic strategies such as targeted therapy against signaling pathways.
https://www.hal.inserm.fr/inserm-02481934
Contributor : Nathalie Labarriere <>
Submitted on : Monday, February 17, 2020 - 5:14:32 PM Last modification on : Friday, June 19, 2020 - 3:08:56 AM Long-term archiving on: : Monday, May 18, 2020 - 6:54:10 PM
File
Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed
until : jamais
Nathalie Labarrière, Amir Khammari, François Lang, Brigitte Dreno. Is antigen specificity the key to efficient adoptive T‑cell therapy?. Immunotherapy, Future Medicine, 2011, ⟨10.2217/IMT.11.16⟩. ⟨inserm-02481934⟩